American Oriental Bioengineering Cash and ST Investments: 83.67M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AOB Cash and ST Investments Rankings
| Overall | 51st percentile | 2186 of 4527 |
| Sector | 62nd percentile | 197 of 519 in Healthcare |
| Industry | 64th percentile | 58 of 163 in Biotechnology |
AOB Cash and ST Investments Range, Past 5 Years
| Minimum | 0.00M | Jun 2001 |
| Maximum | 87.78M | Dec 2006 |
| Average | 16.57M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these AOB related companies
AOB News
$AOB http://stks.co/21aH Chinese biotech, took a beating today, but with forward p/e of 5.25 will watch.
about 23 days ago by Xiphos_Trading
about 23 days ago by Xiphos_Trading
Halter USX China Index Announces 2011 Year End and 4Q Results and Adds New Constituents
Dec 31, 11:25AM Business Wire
Dec 31, 11:25AM Business Wire
$AOB filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1BzO
about 86 days ago by MarketBrief
about 86 days ago by MarketBrief
American Oriental Bioengineering Reports Third Quarter 2011 Financial Results
Nov 14, 6:03PM PR Newswire
Nov 14, 6:03PM PR Newswire
URGENT: $AOB filed to delay releasing quarterly earnings results (SEC Filing Form NT 10Q) http://stks.co/13Y8
about 95 days ago by MarketBrief
about 95 days ago by MarketBrief
American Oriental Bioengineering $AOB delays earnings. No reason given (shares were halted as noted earlier)
about 96 days ago by Street_Insider
about 96 days ago by Street_Insider
American Oriental Bioengineering $AOB trading halted with news pending
about 96 days ago by Street_Insider
about 96 days ago by Street_Insider
American Oriental Bioengineering to Announce Third Quarter 2011 Financial Results on November 8, 2011
Nov 03, 9:15AM PR Newswire
Nov 03, 9:15AM PR Newswire
$FSLR $PEIX $NFLX $AOB $CSIQ - I never tire of these cautionary tales, when folks are all gaga http://chart.ly/knacefw
about 124 days ago by meltedcheese
about 124 days ago by meltedcheese
American Oriental Bioengineering (AOB) Submits Plan to Cure Stock Price Deficiency
Oct 06, 5:02PM Street Insider
Oct 06, 5:02PM Street Insider
$AOB http://chart.ly/jph7wuw $AOB yesterday's heavy volume could be the precursor of a strong upside move.
about 184 days ago by ACInvestorBlog
about 184 days ago by ACInvestorBlog
$AOB
American Oriental Bioengineering Reports Q2 EPS $0.05 vs $0.07 Est
about 187 days ago by Benzinga
about 187 days ago by Benzinga
$AOB http://chart.ly/tecrwmk Chinese biotech big vol today stopped at 50-day EMA so on break above - about $1.28
about 220 days ago by StockTiger
about 220 days ago by StockTiger
$AOB http://chart.ly/juap9pf Long term trend is still down.
Heavy resistance in lows $2s
about 308 days ago by WallStreetPro1
about 308 days ago by WallStreetPro1
$AOB http://chart.ly/olnchtg Getting stuck at $2, if it can get over it it may run a little, but $2.20s may be problems too
about 308 days ago by WallStreetPro1
about 308 days ago by WallStreetPro1
$AOB : a huge difference between value and price (assuming it's not fraudulent ). Is this a healthy stock ? I think so !
about 314 days ago by livethelife
about 314 days ago by livethelife
When everyone else is running scared, that's the time to be brave. DD ! $AOB $MSFT $GOOG Buy The Dip ?
about 328 days ago by livethelife
about 328 days ago by livethelife
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AOB | 0.83 | -0.02 | -2.16% | 65.26M |
| SB | 7.23 | -0.18 | -2.44% | 512.53M |
| LLY | 39.31 | -0.21 | -0.53% | 45.51B |
| XRA | 3.57 | -0.04 | -1.11% | 311.16M |
| IO | 8.05 | -0.46 | -5.41% | 1.25B |
| GFI | 16.47 | -0.20 | -1.20% | 11.93B |
| ALC | 16.34 | -0.16 | -0.97% | 374.68M |
| DAL | 10.89 | -0.23 | -2.07% | 9.21B |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
| STD | 8.54 | -0.22 | -2.51% | 72.08B |
